Preablative Stimulated Thyroglobulin and Thyroglobulin Reduction Index as Decision-Making Markers for Second Radioactive Iodine Therapy in Patients with Structural Incomplete Response

References

• Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA. 2017;317(13):1338–1348. doi:10.1001/jama.2017.271928362912
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–289. doi:10.3322/caac.2134927253694
   PubMed Web of Science ®Google Scholar
• Castagna MG, Maino F, Cipri C, et al. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol. 2011;165(3):441–446. doi:10.1530/EJE-11-046621750043
   PubMed Web of Science ®Google Scholar
• Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20(12):1341–1349. doi:10.1089/thy.2010.017821034228
   PubMed Web of Science ®Google Scholar
• Mitchell AL, Gandhi A, Scott-Coombes D, Perros P. Management of thyroid cancer: United Kingdom national multidisciplinary guidelines. J Laryngol Otol. 2016;130(S2):S150–S160. doi:10.1017/S002221511600057827841128
   PubMed Web of Science ®Google Scholar
• Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892–2899. doi:10.1210/jc.2005-283816684830
   PubMed Web of Science ®Google Scholar
• Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133. doi:10.1089/thy.2015.002026462967
   PubMed Web of Science ®Google Scholar
• Yang X, Liang J, Li T, Zhao T, Lin Y. Preablative stimulated thyroglobulin correlates to new therapy response system in differentiated thyroid cancer. J Clin Endocrinol Metab. 2016;101(3):1307–1313. doi:10.1210/jc.2015-401626789779
   PubMed Web of Science ®Google Scholar
• Raue F, Frank-Raue K. Thyroid cancer: risk-stratified management and individualized therapy. Clin Cancer Res. 2016;22(20):5012–5021. doi:10.1158/1078-0432.CCR-16-048427742787
   PubMed Web of Science ®Google Scholar
• Luster M, Weber T, Verburg FA. Differentiated thyroid cancer—personalized therapies to prevent overtreatment. Nat Rev Endocrinol. 2014;10(9):563–574. doi:10.1038/nrendo.2014.10024981455
   PubMed Web of Science ®Google Scholar
• Wong KCW, Ng TY, Yu KS, et al. The use of post-ablation stimulated thyroglobulin in predicting clinical outcomes in differentiated thyroid carcinoma - what cut-off values should we use? Clin Oncol (R Coll Radiol). 2019;31(2):e11–e20. doi:10.1016/j.clon.2018.10.00930454940
   PubMed Web of Science ®Google Scholar
• Barres B, Kelly A, Kwiatkowski F, et al. Stimulated thyroglobulin and thyroglobulin reduction index predict excellent response in differentiated thyroid cancers. J Clin Endocrinol Metab. 2019;104(8):3462–3472. doi:10.1210/jc.2018-0268030785995
   PubMed Web of Science ®Google Scholar
• Prpic M, Franceschi M, Romic M, Jukic T, Kusic Z. Thyroglobulin as a tumor marker in differentiated thyroid cancer - clinical considerations. Acta Clin Croat. 2018;57(3):518–527. doi:10.20471/acc.2018.57.03.1631168186
   PubMed Web of Science ®Google Scholar
• Yang X, Liang J, Li TJ, et al. Postoperative stimulated thyroglobulin level and recurrence risk stratification in differentiated thyroid cancer. Chin Med J (Engl). 2015;128(8):1058–1064. doi:10.4103/0366-6999.15508625881600
   PubMed Web of Science ®Google Scholar
• Piccardo A, Arecco F, Puntoni M, et al. Focus on high-risk DTC patients: high postoperative serum thyroglobulin level is a strong predictor of disease persistence and is associated to progression-free survival and overall survival. Clin Nucl Med. 2013;38(1):18–24. doi:10.1097/RLU.0b013e318266d4d823242039
   PubMed Web of Science ®Google Scholar
• Polachek A, Hirsch D, Tzvetov G, et al. Prognostic value of post-thyroidectomy thyroglobulin levels in patients with differentiated thyroid cancer. J Endocrinol Invest. 2011;34(11):855–860. doi:10.3275/776821646855
   PubMed Web of Science ®Google Scholar
• Dessoki N, Nasr I, Badawy A, Ali I. Value of the postablative thyroglobulin measurements for assessment of disease-free status in patients with differentiated thyroid cancer. Indian J Nucl Med. 2019;34(2):118–124. doi:10.4103/ijnm.IJNM_142_1831040522
   PubMed Web of Science ®Google Scholar
• Zhao T, Liang J, Guo Z, Li T, Lin Y. In patients with low- to intermediate-risk thyroid cancer, a preablative thyrotropin level of 30 muIU/mL is not adequate to achieve better response to 131I therapy. Clin Nucl Med. 2016;41(6):454–458. doi:10.1097/RLU.000000000000116726914559
   PubMed Web of Science ®Google Scholar
• Ahn J, Song E, Kim WG, et al. Long-term clinical outcomes of papillary thyroid carcinoma patients with biochemical incomplete response. Endocrine. 2020;67(3):623–629. doi:10.1007/s12020-019-02142-131776976
   PubMed Web of Science ®Google Scholar
• Jeon MJ, Kim WG, Park WR, et al. Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma. Eur J Endocrinol. 2014;170(1):23–30. doi:10.1530/EJE-13-052424088549
   PubMed Web of Science ®Google Scholar
• Vaisman A, Orlov S, Yip J, et al. Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma. Head Neck. 2010;32(6):689–698. doi:10.1002/hed.2137120187016
   PubMed Web of Science ®Google Scholar
• Rosario PW, Mineiro Filho AF, Prates BS, Silva LC, Calsolari MR. Postoperative stimulated thyroglobulin of less than 1 ng/mL as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation. Thyroid. 2012;22(11):1140–1143. doi:10.1089/thy.2012.019023050786
   PubMed Web of Science ®Google Scholar
• Avram AM, Rosculet N, Esfandiari NH, et al. Differentiated thyroid cancer outcomes after surgery and activity-adjusted 131I theragnostics. Clin Nucl Med. 2019;44(1):11–20. doi:10.1097/RLU.000000000000232130371575
   PubMed Web of Science ®Google Scholar
• Vaisman F, Momesso D, Bulzico DA, et al. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol (Oxf). 2012;77(1):132–138. doi:10.1111/j.1365-2265.2012.04342.x22248037
   PubMed Web of Science ®Google Scholar
• Vaisman F, Tala H, Grewal R, Tuttle RM. In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. Thyroid. 2011;21(12):1317–1322. doi:10.1089/thy.2011.023222136267
   PubMed Web of Science ®Google Scholar
• Heemstra KA, Liu YY, Stokkel M, et al. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 2007;66(1):58–64. doi:10.1111/j.1365-2265.2006.02685.x17201802
   PubMed Web of Science ®Google Scholar
• Hall FT, Beasley NJ, Eski SJ, Witterick IJ, Walfish PG, Freeman JL. Predictive value of serum thyroglobulin after surgery for thyroid carcinoma. Laryngoscope. 2003;113(1):77–81. doi:10.1097/00005537-200301000-0001412514386
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hua W, Zhang X, Peng J, Liang J, Gao Z. The predictive value for excellent response to initial therapy in differentiated thyroid cancer: preablation-stimulated thyroglobulin better than the TNM stage. Nucl Med Commun. 2018;39(5):405–410. doi:10.1097/MNM.000000000000082729557849
   PubMed Web of Science ®Google Scholar
• Tuttle RM, Alzahrani AS. Risk stratification in differentiated thyroid cancer: from detection to final follow-up. J Clin Endocrinol Metab. 2019;104(9):4087–4100. doi:10.1210/jc.2019-00177
   PubMed Web of Science ®Google Scholar
• Randolph GW, Duh QY, Heller KS, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012;22(11):1144–1152. doi:10.1089/thy.2012.004323083442
   PubMed Web of Science ®Google Scholar
• Cooper DS, Doherty GM, Haugen BR; American Thyroid Association Guidelines Taskforce on Thyroid N, Differentiated Thyroid C. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–1214. doi:10.1089/thy.2009.011019860577
   PubMed Web of Science ®Google Scholar
• Radowsky JS, Howard RS, Burch HB, Stojadinovic A. Impact of degree of extrathyroidal extension of disease on papillary thyroid cancer outcome. Thyroid. 2014;24(2):241–244. doi:10.1089/thy.2012.056723713855
   PubMed Web of Science ®Google Scholar
• Kendler DB, Vaisman F, Corbo R, Martins R, Vaisman M. Preablation stimulated thyroglobulin is a good predictor of successful ablation in patients with differentiated thyroid cancer. Clin Nucl Med. 2012;37(6):545–549. doi:10.1097/RLU.0b013e31824852f822614184
   PubMed Web of Science ®Google Scholar